Phase I Dose Escalation Study of Bortezomib in Combination with Lenalidomide in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1–21 in 28 day...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Attar, Eyal C., Amrein, Philip C., Fraser, James W., Fathi, Amir, McAfee, Steven, Wadleigh, Martha, DeAngleo, Daniel J., Steensma, David, Stone, Richard M., Foster, Julia, Neuberg, Donna, Ballen, Karen K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3969839/
https://ncbi.nlm.nih.gov/pubmed/23773898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.05.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados